{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05856981",
            "orgStudyIdInfo": {
                "id": "SRP-22C102"
            },
            "organization": {
                "fullName": "Sairopa B.V.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors",
            "officialTitle": "An Open-Label, Multicenter, Multi-arm Phase 1 Study Evaluating the Safety and Pharmacokinetics of ADU-1805 in Adults With Advanced Solid Tumors",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "phase-study-evaluating-the-safety-and-pk-of-adu-in-advanced-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-04-03",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-01-04",
            "studyFirstSubmitQcDate": "2023-05-03",
            "studyFirstPostDateStruct": {
                "date": "2023-05-12",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-05-26",
            "lastUpdatePostDateStruct": {
                "date": "2023-05-30",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Sairopa B.V.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This first-in-human, open-label, multicenter, multi-arm dose-escalation study is designed to evaluate the safety, PK, and PD of ADU-1805, an anti- SIRP\u03b1 monoclonal antibody, as monotherapy and in combination with pembrolizumab (anti-PD-1 antibody).",
            "detailedDescription": "The study will start with the ADU-1805 monotherapy dose escalation arm following an i3+3 design until the RP2D is defined. The ADU-1805 plus pembrolizumab dose escalation arm, also following an i3+3 design, will start after clearance of the ADU-1805 monotherapy dose level achieving maximum target engagement (e.g. \u2265 90% target engagement) and will continue until the RP2D for the combination is defined."
        },
        "conditionsModule": {
            "conditions": [
                "Solid Tumor, Adult",
                "Metastatic Solid Tumor",
                "Refractory Cancer"
            ],
            "keywords": [
                "Immunotherapy"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 90,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Monotherapy dose escalation, IV, Q3W, multiple dose levels",
                    "type": "EXPERIMENTAL",
                    "description": "ADU-1805 monotherapy dose escalation",
                    "interventionNames": [
                        "Drug: ADU-1805"
                    ]
                },
                {
                    "label": "Combination dose escalation, IV, Q3W, multiple dose levels, pembrolizumab at fixed dose",
                    "type": "EXPERIMENTAL",
                    "description": "ADU-1805 plus pembrolizumab dose escalation",
                    "interventionNames": [
                        "Drug: ADU-1805",
                        "Drug: Pembrolizumab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "ADU-1805",
                    "description": "anti-SIRP\u03b1 monoclonal antibody",
                    "armGroupLabels": [
                        "Combination dose escalation, IV, Q3W, multiple dose levels, pembrolizumab at fixed dose",
                        "Monotherapy dose escalation, IV, Q3W, multiple dose levels"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Pembrolizumab",
                    "description": "Keytruda",
                    "armGroupLabels": [
                        "Combination dose escalation, IV, Q3W, multiple dose levels, pembrolizumab at fixed dose"
                    ],
                    "otherNames": [
                        "Keytruda"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence and severity of dose limiting toxicity (DLT), treatment-emergent adverse events (TEAEs), and changes from baseline in safety parameters",
                    "description": "Incidence of DLTs and incidence and severity of TEAEs, classified according to NCI-CTCAE v. 5.0",
                    "timeFrame": "First 21 days of treatment"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Pharmacokinetics of ADU-1805 monotherapy and ADU-1805 plus pembrolizumab, serum concentration-time profile and PK parameters",
                    "description": "Maximum concentration (Cmax)",
                    "timeFrame": "Through study completion, up to 2,5 years"
                },
                {
                    "measure": "Pharmacokinetics of ADU-1805 monotherapy and ADU-1805 plus pembrolizumab, serum concentration-time profile and PK parameters",
                    "description": "Time of maximum concentration (Tmax)",
                    "timeFrame": "Through study completion, up to 2,5 years"
                },
                {
                    "measure": "Pharmacokinetics of ADU-1805 monotherapy and ADU-1805 plus pembrolizumab, serum concentration-time profile and PK parameters",
                    "description": "Area under the curve (AUC)",
                    "timeFrame": "Through study completion, up to 2,5 years"
                },
                {
                    "measure": "Immunogenicity of ADU-1805 monotherapy and ADU-1805 plus pembrolizumab",
                    "description": "Incidence of anti-ADU-antibodies",
                    "timeFrame": "Through study completion, up to 2,5 years"
                },
                {
                    "measure": "Pharmacodynamics of ADU-1805 monotherapy and ADU-1805 plus pembrolizumab",
                    "description": "DNA sequencing of SIRP\u03b1 alleles",
                    "timeFrame": "Through end of treatment, up to 2 years"
                },
                {
                    "measure": "Pharmacodynamics of ADU-1805 monotherapy and ADU-1805 plus pembrolizumab",
                    "description": "Target engagement by ADU-1805",
                    "timeFrame": "Through end of treatment, up to 2 years"
                },
                {
                    "measure": "Preliminary Clinical activity of ADU-1805 monotherapy and ADU-1805 plus pembrolizumab",
                    "description": "Overall response per (i)RECIST.",
                    "timeFrame": "Through study completion, up to 2,5 years"
                },
                {
                    "measure": "Preliminary Clinical activity of ADU-1805 monotherapy and ADU-1805 plus pembrolizumab",
                    "description": "Duration of response per (i)RECIST.",
                    "timeFrame": "Through study completion, up to 2,5 years"
                },
                {
                    "measure": "Preliminary Clinical activity of ADU-1805 monotherapy and ADU-1805 plus pembrolizumab",
                    "description": "Disease control per (i)RECIST",
                    "timeFrame": "Through study completion, up to 2,5 years"
                },
                {
                    "measure": "Preliminary Clinical activity of ADU-1805 monotherapy and ADU-1805 plus pembrolizumab",
                    "description": "Duration of disease control per (i)RECIST",
                    "timeFrame": "Through study completion, up to 2,5 years"
                },
                {
                    "measure": "Preliminary Clinical activity of ADU-1805 monotherapy and ADU-1805 plus pembrolizumab",
                    "description": "Progression-free survival per (i)RECIST",
                    "timeFrame": "Through study completion, up to 2,5 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female aged \u226518 years\n* Signed and dated informed consent form\n* Histologically and/or cytologically confirmed diagnosis of metastatic or unresectable solid tumors that are refractory to standard therapy or for which no standard therapy exists\n* Measurable disease according to RECIST (Safety Expansion only)\n* ECOG Performance status of 0 or 1\n* Adequate organ and marrow function\n\nExclusion Criteria:\n\n* Patients that suffer from melanoma, brain tumors, glioblastoma, sarcoma and pancreatic ductal adenocarcinoma (PDAC)\n* Pregnancy or breast-feeding\n* Prior treatment with or receipt of:\n\n  * biological agents, including monoclonal antibodies and immunotherapies, within 28 days prior to the first dose of ADU-1805\n  * chemotherapy, targeted small molecule therapy, hormonal therapy or radiation therapy within 21 days prior to the first dose of ADU-1805 and within 42 days for nitrosoureas and mitomycin C.\n  * anti-SIRP\u03b1 or anti-CD47-directed therapy\n  * systemic chronic steroid therapy or immunosuppressive therapy within 14 days prior to the first dose of ADU-1805\n  * other investigational new drug or investigational device within 28 days prior to the first dose of ADU-1805\n  * vaccine containing live virus within 28 prior to the first dose of ADU-1805\n* Active untreated brain metastases\n* Active infection requiring systemic therapy\n* Impaired cardiac function or clinically significant cardiac disease\n* Current Grade \\>2 toxicity related to prior anti-cancer therapy\n* History of drug-induced severe immune-related adverse reaction\n* Prior severe hypersensitivity to other monoclonal antibodies or ADU-1805 excipients\n* Major surgery within defined period\n* Diagnosis or positive test of HIV, hepatitis B, hepatitis C, or active tuberculosis\n* Allogenic tissue/solid organ transplant\n* Any intercurrent illness that is life-threatening or of such clinical significance that it would interfere with the patient's safety or ability to participate in the study",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Sairopa Clinical Team",
                    "role": "CONTACT",
                    "phone": "0031 85 90 26 939",
                    "email": "clinical@sairopa.com"
                }
            ],
            "locations": [
                {
                    "facility": "Carolina BioOncology Institute - Cancer Research Clinic",
                    "status": "RECRUITING",
                    "city": "Huntersville",
                    "state": "North Carolina",
                    "zip": "28078",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.41069,
                        "lon": -80.84285
                    }
                },
                {
                    "facility": "Gabrail Cancer & Research Center",
                    "status": "RECRUITING",
                    "city": "Canton",
                    "state": "Ohio",
                    "zip": "44718",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.79895,
                        "lon": -81.37845
                    }
                },
                {
                    "facility": "National Institute of Oncology",
                    "status": "RECRUITING",
                    "city": "Chi\u0219in\u0103u",
                    "country": "Moldova, Republic of",
                    "geoPoint": {
                        "lat": 47.00556,
                        "lon": 28.8575
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000582435",
                    "term": "Pembrolizumab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000082082",
                    "term": "Immune Checkpoint Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M349416",
                    "name": "Pembrolizumab",
                    "asFound": "Mg/m2",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2853",
                    "name": "Immunomodulating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                },
                {
                    "id": "M4230",
                    "name": "Antibodies, Monoclonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                }
            ]
        }
    },
    "hasResults": false
}